Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income	$ 48,652	$ 14,384
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	11,805	14,527
Depreciation and amortization	29,899	28,155
Deferred income taxes	18,618	4,814
Change in fair value of contingent obligations	1,350	(1,253)
Debt issuance costs	(1,426)	0
Abandonment of long-lived assets	0	3,749
Excess tax benefits from stock-based compensation	0	(10,825)
Other	703	2,467
Changes in operating assets and liabilities:
Accounts receivable	9,411	45,035
Inventories	5,113	(16,183)
Income taxes	(5,515)	(10,072)
Prepaid expenses and other assets	(2,157)	(3,146)
Accounts payable	2,965	(1,305)
Accrued expenses and other liabilities	(2,334)	(1,699)
Accrued compensation	(1,902)	(152)
Provision for chargebacks	0	103
Deferred revenue	14,006	(1,348)
Net cash provided by operating activities	129,188	67,251
Cash flows from investing activities:
Purchases of property, plant and equipment and other	(42,381)	(56,243)
Net cash used in investing activities	(42,381)	(56,243)
Cash flows from financing activities:
Issuance of common stock upon exercise of stock options	10,799	14,981
Excess tax benefits from stock-based compensation	0	10,825
Taxes paid on behalf of employees for equity activity	(4,184)	(4,590)
Payments of notes payable	(20,000)	0
Distribution to Aptevo	0	(45,000)
Contingent obligation payments	(2,744)	(1,226)
Restricted cash	(1,043)	0
Purchase of treasury stock	(83)	0
Net cash used in financing activities	(17,255)	(25,010)
Effect of exchange rate changes on cash and cash equivalents	(74)	139
Net increase (decrease) in cash and cash equivalents	69,478	(13,863)
Cash and cash equivalents at beginning of period	271,513	312,795
Cash and cash equivalents at end of period	$ 340,991	$ 298,932